Heron Therapeutics (HRTX) Invested Capital (2011 - 2026)

Heron Therapeutics (HRTX) has reported Invested Capital for 15 consecutive years, with $115.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Invested Capital fell 5.64% year-over-year to $115.6 million; the trailing twelve-month figure through Jun 2026 stood at $115.6 million (down 5.64% YoY), and the FY2025 full-year result was $122.2 million, up 1517.18% from the prior year.
• Invested Capital eased to $115.6 million in Q2 2026 per HRTX's latest filing, from $117.4 million in the prior quarter.
• Across five years, Invested Capital topped out at $122.5 million in Q2 2025 and bottomed at -$15.2 million in Q3 2024.
• Historically, Invested Capital has averaged $44.8 million across 4 years, with a median of -$3.5 million in 2023.
• The sharpest annual moves came in 2024 and 2026: Invested Capital sank 303.32% in 2024, then soared 3724.81% in 2026.
• Over 4 years, Invested Capital stood at -$9.7 million in 2023, then gained by 11.17% to -$8.6 million in 2024, then surged by 1517.18% to $122.2 million in 2025, then fell by 5.4% to $115.6 million in 2026.
• According to Business Quant data, Invested Capital over the past three periods registered $115.6 million, $117.4 million, and $122.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.